BDD appoints ex-AstraZeneca VP Joanne Kelley as non-executive director to the Board

October 12, 2018





For immediate release – 12th October 2018


BDD appoints ex-AstraZeneca VP Joanne Kelley as non-executive director to the Board


BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.


Jo is a Life Sciences Business Development professional and brings an outstanding track record of strategy development, deal preparation and execution to the BDD Board.

During a long, successful career at AstraZeneca, Jo had extensive experience of global commercial and general management. In the role of Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals. She has led all types of transactions including M&A, technology licensing and collaboration arrangements. Jo has received a number of awards recognising her deal making achievements from colleagues and peers including recognition from The Pharmaceutical Licensing Group.

After retiring from AstraZeneca Jo has continued to pursue her passion to support UK innovation. She now works as a Director of Alderley Park Ventures and is a non executive director at UMI3, the innovation company of Manchester University.


Commenting on this appointment, Howard Stevens, Chairman of BDD, said: “I am delighted to welcome Jo to the Board, she brings a broad range of experience to the role, including significant licensing experience. I am certain she will play a big part in BDD’s future success as we continue to grow and expand our licensing and collaboration activities.


Commenting on her appointment, Jo said “I am delighted to be joining the Board of BDD at such an exciting time in the company’s expansion. BDD is an innovative and ambitious company with a lot to offer pharma partners”





Further enquiries:


Carol Thomson

BDD Pharma Ltd


Notes to Editors



About BDD


BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD’s OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, sustained release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents in the US, EU and Japan. Supported by investment from Archangels and the Scottish Investment Bank, BDD has in house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans.


For more information visit







Please reload

Featured Posts

BDD Pharma secures license agreement with top pharma company for timed-release OralogiK™ technology

May 30, 2018

Please reload

Recent Posts
Please reload

Please reload

Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square

          BDD Ltd


CLINICAL SITE:   Bio-Images Drug Delivery Ltd

Glasgow Royal Infirmary

84 Castle St


G4 0SF, UK

FORMULATION SITE:  Bio-Images Drug Delivery Ltd

Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse


Contact Us

Clinical Site. +44 (0)141 552 8791

Formulation site. +44 (0)141 552 7752



Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use   

@2020 BDD Ltd